• 1. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 4. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzofurans Dibenzofurans

Dibenzo[b,d]furan-1-ylboronic Acid (CAS No. 162607-19-4): A Key Intermediate in Modern Pharmaceutical Synthesis

Dibenzo[b,d]furan-1-ylboronic acid, identified by the chemical compound code CAS No. 162607-19-4, is a significant intermediate in the realm of pharmaceutical synthesis. This compound belongs to the class of boronic acids, which are widely recognized for their utility in Suzuki-Miyaura cross-coupling reactions—a cornerstone of modern organic synthesis. The structural framework of dibenzo[b,d]furan-1-ylboronic acid consists of a fused bicyclic system, incorporating a furan ring and a benzene ring, which endows it with unique electronic and steric properties.

The importance of dibenzo[b,d]furan-1-ylboronic acid in pharmaceutical research is underscored by its role as a precursor in the synthesis of various bioactive molecules. Boronic acids, including this particular derivative, have garnered considerable attention due to their ability to participate in highly efficient and selective coupling reactions. These reactions are pivotal in constructing complex molecular architectures, which are often essential for achieving the desired pharmacological properties in drug candidates.

In recent years, advancements in medicinal chemistry have highlighted the utility of dibenzo[b,d]furan-based scaffolds in the development of therapeutic agents. The fused ring system provides a rigid structure that can mimic natural products and heterocyclic compounds, which are known to exhibit diverse biological activities. For instance, derivatives of dibenzo[b,d]furan have been explored for their potential in treating neurological disorders, cardiovascular diseases, and even certain types of cancer.

The synthesis of dibenzo[b,d]furan-1-ylboronic acid typically involves multi-step organic transformations, starting from readily available precursors. The introduction of the boronic acid functionality at the 1-position of the dibenzo[b,d]furan core is a critical step, often achieved through lithiation-borylation sequences or other metal-catalyzed processes. These synthetic methodologies have been refined over the years to enhance yield and purity, ensuring that researchers have access to high-quality starting materials for further derivatization.

One of the most compelling aspects of working with dibenzo[b,d]furan-1-ylboronic acid is its versatility in cross-coupling reactions. The Suzuki-Miyaura coupling, in particular, has been employed to attach various aryl or heteroaryl groups to the boronic acid moiety. This allows for the rapid construction of libraries of compounds with tailored biological profiles. Such libraries are invaluable in high-throughput screening campaigns aimed at identifying novel lead compounds for drug development.

Recent studies have demonstrated the application of dibenzo[b,d]furan-derived boronic acids in the synthesis of targeted therapies. For example, researchers have utilized these intermediates to develop small-molecule inhibitors that modulate protein-protein interactions critical for disease pathways. The precision offered by boronic acid-based couplings ensures that these inhibitors can be designed with high specificity, minimizing off-target effects and enhancing therapeutic efficacy.

The role of computational chemistry has also become increasingly prominent in optimizing synthetic routes for dibenzo[b,d]furan-1-ylboronic acid. By leveraging molecular modeling and density functional theory (DFT) calculations, chemists can predict reaction outcomes and identify optimal conditions for synthesis. This computational approach not only accelerates the discovery process but also aids in understanding mechanistic details that might be challenging to observe experimentally.

In conclusion, Dibenzo[b,d]furan-1-ylboronic acid (CAS No. 162607-19-4) represents a vital building block in contemporary pharmaceutical research. Its unique structural features and reactivity make it an indispensable tool for medicinal chemists seeking to develop innovative therapeutic agents. As research continues to evolve, it is likely that new applications and synthetic strategies will emerge, further solidifying its importance in the field.

• 331834-13-0(Benzofuran-5-ylboronic acid)
• 395087-89-5(Dibenzo[b,d]furan-3-ylboronic acid)
• 402936-15-6(Dibenzob,dfuran-2-ylboronic Acid)
• 1432610-21-3(benzofuran-7-ylboronic acid)
• 100124-06-9(Dibenzofuran-4-boronic acid)
• 145238-17-1(Dibenzofuran -4,6 -diborate)
• 1627917-17-2(Naphtho[2,3-b]benzofuran-2-ylboronic acid)
• 860625-79-2(Benzofuran-7-ylboronic acid)
• 851525-10-5((1-benzofuran-6-yl)boronic acid)
• 317830-83-4(Benzofuran-3-ylboronic acid)